title: [Multicenter study of satisfaction with fast-dissolving ebastine, 20 mg/ day, in Mexican patients with allergic rhinitis].
abstract: BACKGROUND
  Allergic rhinitis is an inflammatory disease of the nasal mucosa, with common symptoms, which is essentially characterized by nasal itching, nasal congestion, sneezing, hyaline rhinorrhea and repetitive sneezing. The disease is very common, 15% of the population worldwide suffers it. Among many treatments that have been used to relieve the symptoms of this disease there is a selective inhibitor of H1 receptors, ebastine.
  
  
  OBJECTIVE
  To evaluate patient satisfaction using the scale of Treatment Satisfaction Questionnaire for Medication (TSQM).
  
  
  METHODS
  A multicentric, retrospective, observational study performed in 250 Mexican patients with the diagnosis of intermittent allergic rhinitis (IAR) or persistent allergic rhinitis (PER), confirmed by prick test, specific IgE, or both, treated with lyophilised ebastine in fast-dissolving (FDT) 20 mg at any time in the last two months, prescribed for at least two weeks by their doctor to relieve the symptoms of intermittent allergic rhinitis or persistent allergic rhinitis. We used a validated questionnaire assessment scales, TSQM.
  
  
  RESULTS
  The presentation of ebastine fast-dissolving (FDT) is effective and has good tolerability, over 80% of patients reported comfort and satisfaction using it.
  
  
  CONCLUSIONS
  Assessment of overall satisfaction, efficacy, tolerability and comfort showed that ebastine in fast-dissolving is an antihistamine with clear benefits to encourage compliance.
authors.affiliation: Hospital Juárez de México, México, DF. primo65@prodigy.net.mx
authors.forename: Daniel
authors.initials: D
authors.lastname: Aguilar
authors.forename: A
authors.initials: A
authors.lastname: Arias
authors.forename: Carlos
authors.initials: C
authors.lastname: Báez
authors.forename: Sandra
authors.initials: S
authors.lastname: González
authors.forename: D
authors.initials: D
authors.lastname: Hernández
authors.forename: F J
authors.initials: FJ
authors.lastname: Linares
authors.forename: Aída
authors.initials: A
authors.lastname: López
authors.forename: A
authors.initials: A
authors.lastname: Macías
authors.forename: A
authors.initials: A
authors.lastname: Martínez
authors.forename: H M
authors.initials: HM
authors.lastname: Martínez
authors.forename: N
authors.initials: N
authors.lastname: Martínez
authors.forename: M D
authors.initials: MD
authors.lastname: Mogica
authors.forename: David
authors.initials: D
authors.lastname: Paz
authors.forename: I
authors.initials: I
authors.lastname: Rojo
authors.forename: A
authors.initials: A
authors.lastname: Sánchez
mesh_terms: D000293:Adolescent; D000328:Adult; D002090:Butyrophenones / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008800:Mexico; D008875:Middle Aged; D017060:Patient Satisfaction; D010880:Piperidines / Q000008:administration & dosage* / Q000627:therapeutic use; D012189:Retrospective Studies; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012995:Solubility; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; C058249:ebastine